Bayer HealthCare recently announced the 2011 recipients of the Bayer Hemophilia Awards Program (BHAP). The program was established to help improve the understanding and treatment of hemophilia and related bleeding disorders. Overall, $2.5 million in funding was awarded to 18 researchers in 12 countries.
The recipients were honored at a BHAP awards ceremony held in conjunction with the XXIIIrd Congress of the International Society on Thrombosis and Haemostasis in Kyoto, Japan, on July 23-29, 2011.
BHAP is designed to reduce the impact of bleeding disorders on individuals and their communities, and to support “the next generation of care” and treatment options globally for people with hemophilia. BHAP funds research studies to better understand inhibitor development and methods for treatment, gene therapy and joint care to the development of pediatric care models in underserved markets.
Among the 2011 BHAP recipients are:
- John Sheehan, MD, University of Wisconsin, for “Contribution of the Heparin Binding Exosite to Factor IX Clearance and in Vivo Activity”
- Carol Miao, PhD, Seattle Children’s Research Institute, for “Immunomodulation to Eradicate Anti-Factor VIII Inhibitory Antibodies”
- Paris Margaritis, PhD, The Children’s Hospital of Philadelphia, for “The Role of EPCR on FVIIa-Mediated Hemostasis”
“We’re very pleased to award and congratulate these future hemophilia thought leaders for their exemplary passion, talent and expertise,” said John E. Murphy, PhD, Director, Molecular Biology, Biologics Research, Bayer HealthCare. “BHAP is a reflection of Bayer’s commitment to expanding the scientific and clinical knowledge that improves patient care.”
Source: PRNewswire, July 28, 2011
